Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mechanical sensing and reprogramming of CAR-engineered lymphocytes for next-generation ACT cancer immunotherapy

Project description

Cancer immunotherapy with improved mechanical sensing

Immunotherapy has so far demonstrated reduced clinical efficacy against solid tumours. Most efforts to improve immune cell therapies have focused on biochemical interactions, overlooking the physical properties of cells. Emerging evidence indicates that soft cancer cells are more resistant to immune-mediated cell killing, suggesting that mechanical factors could be exploited therapeutically. The ERC-funded MechanoCAR project explores this largely uncharted territory and proposes to reprogramme CAR-T and CAR-NK immune cells with enhanced cytotoxic potential. The idea is to identify the mechanical sensing mechanisms of these cells and develop innovative reprogramming strategies. The MechanoCAR approach will be validated in advanced tumour models and patient-derived organoids in a bid to improve treatment outcomes of challenging cancers.

Objective

Adoptive cell transfer (ACT) with cytotoxic lymphocytes, including chimeric antigen receptor (CAR)-T cells, is a powerful immunotherapy already demonstrating remarkable success against certain blood cancers. However, its efficacy in treating solid tumors remains limited, with durable responses being rare. Current strategies to improve ACT therapy focus predominantly on biochemical interactions between immune cells and cancer cells. Yet, emerging evidence highlights the significant influence of biomechanical cues in shaping immune responses and therapeutic outcomes. For instance, the mechanical properties of cancer cells, such as cellular softness, can confer resistance to immune cell-mediated killing, while rigidifying cancer cells can sensitize them toward immune attack leading to enhanced immunotherapy.
MechanoCAR explores a novel, under-explored approach: mechanical reprogramming of cytotoxic lymphocytes, including CAR-T and CAR natural killer (NK) cells. We hypothesize that enhancing the mechano-sensitivity of the lymphocytes could overcome some of the key limitations of ACT therapies, particularly against resistant tumors. First, we aim to uncover and characterize the mechano-sensing and mechano-transduction mechanisms of CARs. Next, we will develop and test innovative mechanical reprogramming strategies to enhance the cytotoxic potential of CAR-T/NK cells in advanced tumor models and further explore the therapeutic potential using patient-derived organoids.
This ambitious and high-reward research has the potential to transform ACT cancer immunotherapy. It addresses significant gaps in current biochemical-centric approaches by introducing a new paradigm focusing on mechanical modulation. If successful, it will provide groundbreaking insights into mechano-immunology, offer a blueprint for designing the next-generation ACT immunotherapies, and ultimately improve treatment outcomes for patients with challenging cancers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-COG

See all projects funded under this call

Host institution

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Net EU contribution
€ 2 175 000,00
Address
BATIMENT CE 3316 STATION 1
1015 Lausanne
Switzerland
Region
Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 2 175 000,00

Beneficiaries (1)